Background Background Genetic variations might
Genetic variations might modify associations between schizomodify associations between schizophrenia and cannabis or tobacco use. phrenia and cannabis or tobacco use.
Aims Aims To examine whether variants
To examine whether variants within the cannabinoid receptor ( within the cannabinoid receptor (CNR1 CNR1) ) and and a a 7 7 nicotinic receptor ( nicotinic receptor (CHRNA7 CHRNA7) genes ) genes are associated with schizophrenia, and are associated with schizophrenia, and whether these effects vary according to whether these effects vary according to cannabis or tobacco use. We also cannabis or tobacco use. We also examined a putative interaction between examined a putative interaction between cannabis and Val cannabis and Val 158 158 Met within the Met within the catecholcatechol-O O-methyltransferase gene -methyltransferase gene ( (COMT COMT). ).
Method Method Genotype effects of
Genotype effects of CHRNA7 CHRNA7 and and CNR1
CNR1were studied in a case^control were studied in a case^control sample of 750 individuals with sample of 750 individuals with schizophrenia and 688 controls, with schizophrenia and 688 controls, with interactions for these genes studied in interactions for these genes studied in small subsamples. A case-only design of small subsamples. A case-only design of 493 ofthe schizophrenia group was used to 493 ofthe schizophrenia group was used to examine interactions between cannabis examine interactions between cannabis use and use and COMT COMT. .
Results
Results There was no evidence of There was no evidence of association between schizophrenia and association between schizophrenia and CNR1 CNR1 (OR (OR¼0.97,95% CI 0.82^1.13) or 0.97,95% CI 0.82^1.13) or CHRNA7 CHRNA7 (OR (OR¼1.07,95% CI 0.77^1.49) 1.07,95% CI 0.77^1.49) genotypes, or of interactions between genotypes, or of interactions between tobacco use and tobacco use and CHRNA7 CHRNA7, or cannabis use , or cannabis use and and CNR1
CNR1or or COMT COMT genotypes. genotypes.
Conclusions
Conclusions Neither Neither CNR1 CNR1nor nor CHRNA7 CHRNA7 variation appears to alter therisk variation appears to alter the risk of schizophrenia. Furthermore, our of schizophrenia.Furthermore, our results do not supportthe presence of results do not supportthe presence of different effects of cannabis use on different effects of cannabis use on schizophrenia according to variation within schizophrenia according to variationwithin COMT COMT. .
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Schizophrenia is associated with increased
Schizophrenia is associated with increased use of cannabis and tobacco compared with use of cannabis and tobacco compared with the general population, although reasons the general population, although reasons for these associations have not been clearly for these associations have not been clearly elucidated. There is some evidence that elucidated. There is some evidence that people with schizophrenia may use tobacco people with schizophrenia may use tobacco to alleviate neurophysiological deficits asto alleviate neurophysiological deficits associated with this disorder (Adler sociated with this disorder (Adler et al et al, , 1993; Olincy 1993; Olincy et al et al, 1998) , and that this is , 1998), and that this is mediated through effects at the mediated through effects at the a a 7 7 nicotinic nicotinic acetylcholine receptor (CHRNA7) (Gray acetylcholine receptor (CHRNA7) (Gray et et al al, 1996; Stevens , 1996; Stevens et al et al, 1998 ). An associa-, 1998 ). An association between schizophrenia and a putative tion between schizophrenia and a putative functional variant, -86C/T, within the functional variant, -86C/T, within the CHRNA7 gene ( CHRNA7 gene (CHRNA7 CHRNA7) has been re-) has been reported (Leonard ported (Leonard et al et al, 2002) and warrants , 2002) and warrants further exploration. further exploration.
The main psychoactive compound withThe main psychoactive compound within cannabis is delta-9-tetrahydrocannabinol in cannabis is delta-9-tetrahydrocannabinol ( (D D 9 9 -THC), which acts through the CNR1 -THC), which acts through the CNR1 cannabinoid receptor. An increased incicannabinoid receptor. An increased incidence of psychotic disorders in people using dence of psychotic disorders in people using cannabis has been observed (Arseneault cannabis has been observed (Arseneault et al et al, 2002; Zammit , 2002; Zammit et al et al, 2002 ) and a , 2002) and a putative interaction between cannabis use putative interaction between cannabis use and variation within the catecholand variation within the catechol-O O--methyltransferase ( methyltransferase (COMT COMT) gene on risk of ) gene on risk of psychosis has also been reported (Caspi psychosis has also been reported (Caspi et et al al, 2005) . Findings from relatively small , 2005). Findings from relatively small studies examining association between studies examining association between CNR1 CNR1 genetic variation -most commonly genetic variation -most commonly at the single nucleotide polymorphism at the single nucleotide polymorphism (SNP) rs (SNP) rs1049353 -and schizophrenia have 1049353 -and schizophrenia have been inconsistent, and it was considered been inconsistent, and it was considered worth while to examine this in a substanworth while to examine this in a substantially larger sample than has been studied tially larger sample than has been studied thus far. thus far.
The main aims of our study were to inThe main aims of our study were to investigate whether variations at -86C/T vestigate whether variations at -86C/T within within CHRNA7 CHRNA7 and at rs1049353 within and at rs1049353 within CNR1 CNR1 were associated with schizophrenia, were associated with schizophrenia, and whether these relationships differed acand whether these relationships differed according to use of tobacco or cannabis. We cording to use of tobacco or cannabis. We also investigated whether there was any evialso investigated whether there was any evi McGuffin et al et al, 1991) and , 1991) and Global Assessment Scale (GAS; Endicott Global Assessment Scale (GAS; Endicott et al et al, 1976) were also completed. High , 1976) were also completed. High levels of reliability ( levels of reliability (k k4 40.8) were achieved 0.8) were achieved between raters for diagnoses and rating between raters for diagnoses and rating scale items. Controls were unrelated blood scale items. Controls were unrelated blood donors ascertained from the same regions donors ascertained from the same regions as the majority of the patients. Given the as the majority of the patients. Given the prevalence of schizophrenia and the fact prevalence of schizophrenia and the fact that people taking regular medication canthat people taking regular medication cannot be blood donors in the UK, it was not not be blood donors in the UK, it was not deemed necessary to screen the control deemed necessary to screen the control group for schizophrenia to retain statistical group for schizophrenia to retain statistical power (Owen power (Owen et al et al, 1997) . Ethical approval , 1997). Ethical approval was granted for this study and informed was granted for this study and informed consent was obtained from all participants. consent was obtained from all participants.
All study participants were White, with All study participants were White, with both parents born in the UK or Ireland. All both parents born in the UK or Ireland. All cases of schizophrenia satisfied DSM-IV cases of schizophrenia satisfied DSM-IV criteria (American Psychiatric Association, criteria (American Psychiatric Association, 1994) for consensus lifetime diagnosis of 1994) for consensus lifetime diagnosis of the disorder, made by two independent the disorder, made by two independent raters. The following phenotypes, deterraters. The following phenotypes, determined mined a priori a priori, were examined in relation , were examined in relation to -86C/T and rs1049353 genotype: to -86C/T and rs1049353 genotype:
(a) (a) age at onset, defined as the age at which age at onset, defined as the age at which psychiatric help for psychotic symppsychiatric help for psychotic symptoms was first sought; toms was first sought;
(b) (b) worst-ever GAS score, ranging from 0 worst-ever GAS score, ranging from 0 (most severe) to 100 (least severe); (most severe) to 100 (least severe); Data on tobacco and cannabis use were Data on tobacco and cannabis use were obtained from interview and case-note obtained from interview and case-note records for 657 of the schizophrenia group. records for 657 of the schizophrenia group. Questions regarding the age at which the Questions regarding the age at which the person first started using cannabis or person first started using cannabis or tobacco were only introduced during the tobacco were only introduced during the latter part of the sample recruitment, and latter part of the sample recruitment, and these data were therefore available for only these data were therefore available for only 22% of cases in which the person reported 22% of cases in which the person reported ever using these substances. Substance use ever using these substances. Substance use data were not collected initially for the condata were not collected initially for the control group, and unfortunately most memtrol group, and unfortunately most members of the control group were not asked bers of the control group were not asked at the initial interview for permission to at the initial interview for permission to contact them again for further information. contact them again for further information. As a result of this, cannabis use data were As a result of this, cannabis use data were available for only 116 controls and tobacco available for only 116 controls and tobacco use data for 49 controls. use data for 49 controls.
Genotyping Genotyping
The The CHRNA7 CHRNA7 promoter polymorphism promoter polymorphism -86C/T was genotyped as a restriction--86C/T was genotyped as a restrictionfragment length polymorphism using the fragment length polymorphism using the restriction enzyme restriction enzyme Hph1
Hph1 (New England (New England Biolabs, Ipswich, Massachusetts, USA). The Biolabs, Ipswich, Massachusetts, USA). The primers were 5 primers were 5' '-agtacctcccgctcacacctcg-3 -agtacctcccgctcacacctcg-3' ' and 5 and 5' '-atgttgagtcccggagctg-3 -atgttgagtcccggagctg-3' ' as used by as used by Leonard Leonard et al et al (2002) . The product was am-(2002). The product was amplified using the GC-RICH PCR System plified using the GC-RICH PCR System (Roche Diagnostics, Basel, Switzerland), (Roche Diagnostics, Basel, Switzerland) , and the 272 base pairs fragment was and the 272 base pairs fragment was digested with digested with Hph1
Hph1 resulting in two fragresulting in two fragments of 79 bp and 193 bp with the T allele. ments of 79 bp and 193 bp with the T allele. The products were run out on a 1.5% The products were run out on a 1.5% agarose gel and visualised using ethidium agarose gel and visualised using ethidium bromide. bromide.
The The CNR1 CNR1 polymorphism rs1049353 polymorphism rs1049353 was genotyped by fluorescence polarisation was genotyped by fluorescence polarisation using an AcycloPrime kit (PerkinElmer, using an AcycloPrime kit (PerkinElmer, Waltham, Massachusetts, USA) and the Waltham, Massachusetts, USA) and the output was read on an LJL Biosystems output was read on an LJL Biosystems (Sunnyvale, California, USA) plate reader. (Sunnyvale, California, USA) plate reader. A 297 bp amplimere was amplified using A 297 bp amplimere was amplified using primers 5 primers 5' '-ttccctcttgtgaaggcact-3 -ttccctcttgtgaaggcact-3' ' and 5 and 5' '--tcattgagcatggtaaagtt-3 tcattgagcatggtaaagtt-3' '. The SNP was at . The SNP was at position 125. The extension primer used position 125. The extension primer used in the fluorescence polarisation assay was in the fluorescence polarisation assay was 5 5' '-catggttaccttggcaatcttgac-3 -catggttaccttggcaatcttgac-3' '. The . The COMT COMT markers were genotyped using SNaPshot markers were genotyped using SNaPshot (Applied Biosystems, Foster City, California, (Applied Biosystems, Foster City, California, USA) using an ABI3100 sequencer. Details USA) using an ABI3100 sequencer. Details of primers and reaction conditions are proof primers and reaction conditions are provided in Appendix 1 at http://www.cardiff. vided in Appendix 1 at http://www.cardiff. ac.uk/medicine/psychological_medicine/pub_ ac.uk/medicine/psychological_medicine/pub_ data/comt.htm. data/comt.htm.
Analysis Analysis
The reference participants for the analyses The reference participants for the analyses were those with genotypes that were CC were those with genotypes that were CC homozygous for -86C/T, GG homozygous homozygous for -86C/T, GG homozygous for rs1049353, AA homozygous for for rs1049353, AA homozygous for rs737865, AA homozygous for rs165599, rs737865, AA homozygous for rs165599, and homozygous for the Met allele at and homozygous for the Met allele at Val Val 158 158 Met within Met within COMT COMT. Only 0.4% of . Only 0.4% of our participants were homozygous for our participants were homozygous for the T allele at the -86C/T locus, and the T allele at the -86C/T locus, and they were therefore grouped with the C/T they were therefore grouped with the C/T heterozygotes. heterozygotes.
Logistic regression was used to examine Logistic regression was used to examine associations between dichotomous outassociations between dichotomous outcomes and genotypes. A dominance genetic comes and genotypes. A dominance genetic model, as described above, was examined model, as described above, was examined for -86C/T, whereas additive models were for -86C/T, whereas additive models were used for the used for the CNR1 CNR1 and and COMT COMT variants variants (Lewis, 2002) . For the study of continuous (Lewis, 2002) . For the study of continuous phenotypic outcomes, linear regression was phenotypic outcomes, linear regression was used. However, for age at onset, where used. However, for age at onset, where assumptions of normality were not met, data assumptions of normality were not met, data were ln-transformed prior to regression were ln-transformed prior to regression modelling. Statistical interactions on a modelling. Statistical interactions on a multiplicative scale between substance use multiplicative scale between substance use and genotype on risk of schizophrenia were and genotype on risk of schizophrenia were investigated using a likelihood ratio test investigated using a likelihood ratio test within the logistic regression models. For within the logistic regression models. For  Val  Val   158 158 Met, however, as no association was Met, however, as no association was observed between this SNP and cannabis observed between this SNP and cannabis use in the Dunedin cohort (Caspi use in the Dunedin cohort (Caspi et al et al, , 2005) , we used a case-only approach to 2005), we used a case-only approach to investigate possible gene-environment investigate possible gene-environment interactions because this is statistically interactions because this is statistically more powerful (Khoury & Flanders, more powerful (Khoury & Flanders, 1996) . The case-only analysis was also used 1996). The case-only analysis was also used for rs737865 and rs165599 within for rs737865 and rs165599 within COMT COMT. . Haplotypes for Haplotypes for COMT COMT were examined were examined using UNPHASED, version 3.0 (Dudbridge, using UNPHASED, version 3.0 (Dudbridge, 2003 (Dudbridge, ). 2003 .
This study had greater than 95% power This study had greater than 95% power to detect an additive genetic effect with an to detect an additive genetic effect with an odds ratio of 1.4 or above at odds ratio of 1.4 or above at a a¼0.05 for 0.05 for the the CNR1 CNR1 and and COMT COMT variants examined. variants examined. This study also had greater than 95% This study also had greater than 95% power to find an association between power to find an association between -86C/T variation and schizophrenia based -86C/T variation and schizophrenia based on frequencies of CC genotype of 0.91 in on frequencies of CC genotype of 0.91 in the control group and 0.84 in the schizothe control group and 0.84 in the schizophrenia group, as observed by Leonard phrenia group, as observed by Leonard et et al al (2002) . The interaction odds ratio (2002 
, and our case-only approach had more than and our case-only approach had more than 90% power to detect an interaction odds 90% power to detect an interaction odds ratio of as low as 1.5, at ratio of as low as 1.5, at a a¼0.05. 0.05.
Sensitivity analysis Sensitivity analysis
Some participants were likely to have Some participants were likely to have started using tobacco or cannabis after the started using tobacco or cannabis after the onset of schizophrenia and it is possible onset of schizophrenia and it is possible that this could obscure and complicate that this could obscure and complicate interpretation of results from this study. interpretation of results from this study. Examination of the association between Examination of the association between schizophrenia and genotypes was therefore schizophrenia and genotypes was therefore repeated with analyses restricted to cases repeated with analyses restricted to cases where the onset of substance use was rewhere the onset of substance use was reported to be at least 1 year prior to age at ported to be at least 1 year prior to age at schizophrenia onset. schizophrenia onset.
RESULTS RESULTS
There were 838 participants with schizoThere were 838 participants with schizophrenia who were genotyped for any of phrenia who were genotyped for any of
(n n¼575). Data on cannabis and 575). Data on cannabis and tobacco use were missing for 96 (11.5%) tobacco use were missing for 96 (11.5%) and 107 (12.8%) of these respectively. Of and 107 (12.8%) of these respectively. Of those with substance use data, 276 partithose with substance use data, 276 participants (37.2%) had ever used cannabis, cipants (37.2%) had ever used cannabis, and 531 (72.6%) had ever used tobacco. and 531 (72.6%) had ever used tobacco.
CHRNA7 CHRNA7
The -86C/T genotypes were in HardyThe -86C/T genotypes were in HardyWeinberg equilibrium in both the schizoWeinberg equilibrium in both the schizophrenia group ( phrenia group (w w 2 2 ¼0.01, 0.01, P P¼0.76) and the 0.76) and the control group ( control group (w w 2 2 ¼0.01, 0.01, P P¼0.92). As 0.92). As shown in Table 1 , there was no evidence shown in Table 1 , there was no evidence for any association between -86C/T genofor any association between -86C/T genotype and schizophrenia (CT/TT genotypes type and schizophrenia (CT/TT genotypes OR OR¼ 1.07, 95% CI 0.77-1.49; 1.07, 95% CI 0.77-1.49; P P¼0.70). 0.70). There was little evidence of any difference There was little evidence of any difference in the effect of genotype on schizophrenia in the effect of genotype on schizophrenia between those who smoked (schizophrenia between those who smoked (schizophrenia group group n n¼473, controls 473, controls n n¼24; OR 24; OR¼3.0, 3.0, 95% CI 0.4-22.9) and those who did not 95% CI 0.4-22.9) and those who did not (schizophrenia group (schizophrenia group n n¼186, controls 186, controls n n¼25; OR 25; OR¼1.7, 95% CI 0.4-7.7; 1.7, 95% CI 0.4-7.7; interaction likelihood ratio test interaction likelihood ratio test w w
As tobacco use data were 0.65). As tobacco use data were available only for a small proportion of the available only for a small proportion of the control group, a more powerful case-only control group, a more powerful case-only analysis was also used, and this also failed analysis was also used, and this also failed to provide any evidence for interaction to provide any evidence for interaction ( (n n¼659; odds ratio for tobacco use by 659; odds ratio for tobacco use by CHRNA7 CHRNA7 genotype 0.89, 95% CI 0.53-genotype 0.89, 95% CI 0.53-1.48).
1.48).
There were 123 in the schizophrenia There were 123 in the schizophrenia group with data relating to age of first group with data relating to age of first using tobacco, and 104 (85%) of these using tobacco, and 104 (85%) of these claimed to have started using tobacco prior claimed to have started using tobacco prior to the onset of schizophrenia. In the sensito the onset of schizophrenia. In the sensitivity analysis there was similarly little evitivity analysis there was similarly little evidence of any difference in the effect of dence of any difference in the effect of genotype on schizophrenia between nongenotype on schizophrenia between nonsmokers and those smoking prior to illness smokers and those smoking prior to illness onset ( onset (n n¼110; OR 110; OR¼2.7, 95% CI 0. 2.6, 95% CI 1.4-4.7; CT/TT genotypes OR CT/TT genotypes OR¼4.6, 95% CI 0.4-4.6, 95% CI 0.4-53.0; interaction likelihood ratio test as 53.0; interaction likelihood ratio test as above, above, P P¼0.65). Tobacco use was not asso-0.65). Tobacco use was not associated with -86C/T genotype (OR ciated with -86C/T genotype (OR¼0.9, 0.9, 95% CI 0.5-1.5). 95% CI 0.5-1.5).
Results for associations between -86C/T Results for associations between -86C/T genotype and various phenotypes within genotype and various phenotypes within schizophrenia are presented in Table 2 . schizophrenia are presented in Table 2 . There was weak evidence ( There was weak evidence (P P¼0.07) that 0.07) that participants with the CT/TT genotypes participants with the CT/TT genotypes had a younger age of onset, by approxihad a younger age of onset, by approximately 2 years on average, than those mately 2 years on average, than those homozygous for the C allele. homozygous for the C allele.
CNR1 CNR1
Genotypes at rs1049353 were in HardyGenotypes at rs1049353 were in HardyWeinberg equilibrium in both the schizoWeinberg equilibrium in both the schizophrenia group ( phrenia group (w w ¼0.11, d.f. 0.11, d.f.¼1, 1, P P¼0.74). As cannabis 0.74). As cannabis use data were again available for only a use data were again available for only a small proportion of the control group, a small proportion of the control group, a case-only analysis was used, and this also case-only analysis was used, and this also failed to provide any evidence for interfailed to provide any evidence for interaction ( action (n n¼706; odds ratio for cannabis 706; odds ratio for cannabis use by use by CNR1 CNR1 genotype 0.83, 95% CI genotype 0.83, 95% CI 0.65-1.05). 0.65-1.05).
As part of the sensitivity analysis, there As part of the sensitivity analysis, there were 71 individuals in the schizophrenia were 71 individuals in the schizophrenia group with data relating to age of first group with data relating to age of first using cannabis, and 64 (90%) of these using cannabis, and 64 (90%) of these reported first use prior to onset of schizoreported first use prior to onset of schizophrenia. As in the main analysis, there phrenia. 
DISCUSSION DISCUSSION
There was no evidence for any association There was no evidence for any association between between CHRNA7 CHRNA7 or or CNR1 CNR1 genotype genotype and schizophrenia in our sample, and also and schizophrenia in our sample, and also 4 0 4 4 0 4 AUTHOR'S PROOF AUTHOR'S PROOF (2002) screened the core promoter region of the full-length gene and reported an of the full-length gene and reported an association between schizophrenia and association between schizophrenia and variant -86C/T. Although we found no variant -86C/T. Although we found no evidence for an association between the evidence for an association between the promoter SNP -86C/T and schizophrenia, promoter SNP -86C/T and schizophrenia, CT/TT genotypes occurred slightly more CT/TT genotypes occurred slightly more frequently in participants with schizofrequently in participants with schizophrenia than in controls, in a direction conphrenia than in controls, in a direction consistent with the findings by Leonard sistent with the findings by Leonard et al et al (2002) . However, we observed a much (2002) . However, we observed a much smaller difference in CC frequency of less smaller difference in CC frequency of less than 1%, as opposed to the 7% reported than 1%, as opposed to the 7% reported in the original study (Leonard in the original study (Leonard et al et al, 2002) . , 2002). People with schizophrenia commonly People with schizophrenia commonly display evidence of sensory attention imdisplay evidence of sensory attention impairments (Adler pairments (Adler et al et al, 1982; Leonard , 1982; Leonard et et al al, 1996) , including deficits in pre-pulse in-, 1996), including deficits in pre-pulse inhibition and P50 gating response (Braff & hibition and P50 gating response (Braff & Saccuzzo, 1985; Braff Saccuzzo, 1985; Braff et al et al, 1992; Waldo , 1992; Waldo et al et al, 1994) . Improvements in such neuro-, 1994) . Improvements in such neurophysiological deficits in people with schizophysiological deficits in people with schizophrenia following cigarette smoking have phrenia following cigarette smoking have been reported (Adler been reported (Adler et al et al, 1993; Olincy , 1993; Olincy et et al al, 1998) , with similar improvements ob-, 1998), with similar improvements observed following nicotine administration served following nicotine administration in animal models (Bickford & Wear, in animal models (Bickford & Wear, 1995; Stevens 1995; Stevens et al et al, 1996 Stevens et al et al, , 1998 . Specific , 1996 Specific , , 1998 . Specific agonists of the agonists of the a a 7 7 receptor (CHRNA7) norreceptor (CHRNA7) normalise sensory gating deficits in animal malise sensory gating deficits in animal models (Stevens models (Stevens et al et al, 1998) , whereas evi-, 1998), whereas evidence for genetic linkage to the P50 deficit dence for genetic linkage to the P50 deficit and, to a lesser extent, to schizophrenia, and, to a lesser extent, to schizophrenia, has been reported for chromosome band has been reported for chromosome band 15q14, an area that contains CHRNA7 15q14, an area that contains CHRNA7 (Coon (Coon et al et al, 1993; Freedman , 1993; Freedman et al et al, 1997; , 1997; Leonard Leonard et al et al, 1998) . , 1998). Despite this support, from a variety of Despite this support, from a variety of sources, that sources, that CHRNA7 CHRNA7 is a good candidate is a good candidate gene for schizophrenia, there is weak evigene for schizophrenia, there is weak evidence at present that variation within this dence at present that variation within this gene is associated with the disorder (Riley gene is associated with the disorder (Riley et al et al, 2000; Xu , 2000; Xu et al et al, 2001; Leonard , 2001; Leonard et al et al, , 2002; Gault 2002; Gault et al et al, 2003; Li , 2003; Li et al et al, 2004; , 2004; Fan Fan et al et al, 2006) . However, given the , 2006). However, given the findings from experimental studies of the findings from experimental studies of the effect of nicotine on neurophysiological effect of nicotine on neurophysiological deficits in both animal models and humans, deficits in both animal models and humans, as described earlier, it may be that any as described earlier, it may be that any association between association between CHRNA7 CHRNA7 and and schizophrenia is mediated by impairments schizophrenia is mediated by impairments in sensory gating or other related physioloin sensory gating or other related physiological responses. In the study by Leonard gical responses. In the study by Leonard et et al al (2002) , presence of the T allele at - (2002), presence of the T allele at -86C/T was also associated with reduced in-86C/T was also associated with reduced inhibition of the P50 response in the control hibition of the P50 response in the control group, and although two other studies did group, and although two other studies did not replicate this finding (Gault not replicate this finding (Gault et al ). There is a clear need for research into need for research into CHRNA7 CHRNA7 variation variation in relation to neurophysiological deficits in relation to neurophysiological deficits in well-designed and adequately powered in well-designed and adequately powered studies to address this further. studies to address this further.
CNR1 CNR1, , COMT
COMT and cannabis and cannabis
We found no evidence of association beWe found no evidence of association between the tween the CNR1 CNR1 locus rs1049353 and locus rs1049353 and schizophrenia, consistent with the overall schizophrenia, consistent with the overall findings previously reported for this variant findings previously reported for this variant from two much smaller studies ( . However, different alleles were associated with increased risk in these two associated with increased risk in these two studies, and the association in one of the studies, and the association in one of the studies was again observed only for a studies was again observed only for a subgroup of participants, this time with subgroup of participants, this time with hebephrenic schizophrenia. hebephrenic schizophrenia.
The The CNR1 CNR1 gene is located on 6q14-15, gene is located on 6q14-15, a region of replicated linkage for schizoa region of replicated linkage for schizophrenia (Lewis phrenia (Lewis et al et al, 2003) . There are four , 2003). There are four SNPs within SNPs within CNR1 CNR1 on HapMap that have on HapMap that have a heterozygosity in European populations a heterozygosity in European populations greater than 0.1; three of these are in the greater than 0.1; three of these are in the 3 3' ' untranslated region whereas rs1049353 untranslated region whereas rs1049353 is a synonymous SNP found within exon is a synonymous SNP found within exon 1. The relatively small size of 1. The relatively small size of CNR1 CNR1, the , the limited variation within the gene and its limited variation within the gene and its linkage disequilibrium structure mean it is linkage disequilibrium structure mean it is unlikely that a substantial effect on schizounlikely that a substantial effect on schizophrenia risk is conferred by variation withphrenia risk is conferred by variation within this gene, given our findings and the lack in this gene, given our findings and the lack of other consistent associations reported to of other consistent associations reported to date. date.
We also failed to find any supporting We also failed to find any supporting evidence for a differential effect of cannabis evidence for a differential effect of cannabis use on psychosis risk according to variation use on psychosis risk according to variation at Val at Val 158 158 Met within Met within COMT COMT. In the Dunedin . In the Dunedin study evidence for an interaction was obstudy evidence for an interaction was observed only for people first using cannabis served only for people first using cannabis by age 18 years, but not for those using it by age 18 years, but not for those using it after this age (Caspi after this age (Caspi et al et al, 2005) . One ex-, 2005) . One explanation proposed for this was that there planation proposed for this was that there may exist a sensitive or even critical period may exist a sensitive or even critical period of risk when the influence of cannabis exof risk when the influence of cannabis exposure is moderated by posure is moderated by COMT COMT genotype. genotype. In our study we failed to find evidence for In our study we failed to find evidence for an interaction between cannabis use and an interaction between cannabis use and COMT COMT genotype even when restricting the genotype even when restricting the analysis to participants who claimed to analysis to participants who claimed to have first used cannabis by the same cuthave first used cannabis by the same cutoff period of age 18 years, despite more off period of age 18 years, despite more than adequate statistical power to replicate than adequate statistical power to replicate the original findings. Furthermore, in conthe original findings. Furthermore, in contrast to the findings by Caspi trast to the findings by Caspi et al et al (2005) , (2005), cannabis use by age 18 years was actually cannabis use by age 18 years was actually less common in participants with schizoless common in participants with schizophrenia homozygous for the Val allele phrenia homozygous for the Val allele compared with those heterozygous for this compared with those heterozygous for this allele or homozygous for Met (5.3%, allele or homozygous for Met (5.3%, 6.4% and 8.7% respectively), 6.4% and 8.7% respectively), although this although this was not significantly different. was not significantly different.
Limitations to the interpretation of Limitations to the interpretation of our results our results
This study was adequately powered to exThis study was adequately powered to examine main effects on risk of schizoamine main effects on risk of schizophrenia, suggesting it is unlikely that phrenia, suggesting it is unlikely that variations in variations in CNR1 CNR1 or or CHRNA7 CHRNA7 are are important risk factors for schizophrenia. important risk factors for schizophrenia. Furthermore, this study was adequately Furthermore, this study was adequately powered for studies of interactions using a powered for studies of interactions using a case-only design, but this approach is case-only design, but this approach is dependent on the assumption of no dependent on the assumption of no genotype-exposure association in the popugenotype-exposure association in the population. For lation. For COMT COMT this assumption is likely this assumption is likely to be a reasonable one, given that no assoto be a reasonable one, given that no association with cannabis use was observed in ciation with cannabis use was observed in the Dunedin cohort (Caspi the Dunedin cohort (Caspi et al et al, 2005) . , 2005). However, this assumption may be less However, this assumption may be less likely to hold true for likely to hold true for CNR1 CNR1 or or CHRNA7 CHRNA7, , given that cannabis and nicotine act given that cannabis and nicotine act through receptors coded for by these genes, through receptors coded for by these genes, and also given the sporadic reports of assoand also given the sporadic reports of associations between cannabis and tobacco deciations between cannabis and tobacco dependence and pendence and CNR1 CNR1/ /CHRNA7 CHRNA7 genotypes genotypes (Greenbaum (Greenbaum et al et al, 2006; Hopfer , 2006; Hopfer et al et al, , 2006) . For that reason we also conducted 2006). For that reason we also conducted studies of interactions between studies of interactions between CNR1 CNR1 and and cannabis as well as between cannabis as well as between CHRNA7 CHRNA7 and tobacco using a more traditional and tobacco using a more traditional case-control approach, although statistical case-control approach, although statistical power to exclude anything other than large power to exclude anything other than large interaction effects for these two genes using interaction effects for these two genes using this latter approach was limited. this latter approach was limited.
Although we genotyped three SNPs in Although we genotyped three SNPs in COMT COMT that together form a haplotype rethat together form a haplotype reported to be significantly associated with ported to be significantly associated with schizophrenia (Shifman schizophrenia (Shifman et al et al, 2002) , we , 2002), we only genotyped one SNP in each of only genotyped one SNP in each of CNR1 CNR1 and and CHRNA7 CHRNA7. It is not possible therefore . It is not possible therefore to rule out causal effects of variants within to rule out causal effects of variants within these genes that are not in strong linkage these genes that are not in strong linkage disequilibrium with the SNPs we tested. disequilibrium with the SNPs we tested. However, a strong effect of However, a strong effect of CNR1 CNR1 on risk on risk of schizophrenia seems unlikely, given the of schizophrenia seems unlikely, given the linkage disequilibrium structure within this linkage disequilibrium structure within this gene. Our confidence in ruling out such an gene. Our confidence in ruling out such an effect for effect for CHRNA7 CHRNA7 is lower, although we is lower, although we did not feel that the evidence we obtained did not feel that the evidence we obtained was strong enough to warrant further genowas strong enough to warrant further genotyping of typing of CHRNA7 CHRNA7 SNPs, especially given SNPs, especially given the problems resulting from the partial the problems resulting from the partial duplication of this gene, which makes such duplication of this gene, which makes such studies inherently more difficult. studies inherently more difficult.
A final limitation of our study is that, A final limitation of our study is that, unlike the longitudinal data collection in unlike the longitudinal data collection in the Dunedin cohort, our case-control dethe Dunedin cohort, our case-control design relied on people recalling age of first sign relied on people recalling age of first use of cannabis and relating this in time use of cannabis and relating this in time to the date of their first contact with psychito the date of their first contact with psychiatric services. Such data seem inherently atric services. Such data seem inherently more likely to be misclassified than promore likely to be misclassified than prospectively collected data. It is unclear to spectively collected data. It is unclear to what extent any such misclassification what extent any such misclassification might have resulted in an underestimate of might have resulted in an underestimate of the association between cannabis use and the association between cannabis use and genotype in our case-only analysis, and genotype in our case-only analysis, and therefore obscured any true interaction eftherefore obscured any true interaction effect. It would, however, presumably require fect. It would, however, presumably require a substantial amount of misclassification to a substantial amount of misclassification to obscure an interaction effect as strong as obscure an interaction effect as strong as that reported by Caspi and colleagues, that reported by Caspi and colleagues, whereby cannabis use was associated with whereby cannabis use was associated with a 10-fold increase in risk of psychotic disa 10-fold increase in risk of psychotic disorder in those homozygous for valine but order in those homozygous for valine but had no effect in those homozygous for had no effect in those homozygous for methionine (Caspi methionine (Caspi et al et al, 2005) . This finding , 2005). This finding of an interaction effect in the Dunedin coof an interaction effect in the Dunedin cohort was observed only in a subgroup of hort was observed only in a subgroup of participants -those using cannabis by age participants -those using cannabis by age 18 years. Similarly, supportive evidence of 18 years. Similarly, supportive evidence of a putative interaction between cannabis a putative interaction between cannabis use and use and COMT COMT on psychotic symptoms, on psychotic symptoms, following administration of cannabis in an following administration of cannabis in an experimental setting was again observed experimental setting was again observed only in a subgroup of participants with only in a subgroup of participants with schizophrenia, this time those with evischizophrenia, this time those with evidence of pre-existing psychotic traits dence of pre-existing psychotic traits (Henquet (Henquet et al et al, 2006) . Although such find-, 2006). Although such findings are biologically plausible and seem ings are biologically plausible and seem intuitively appealing, substantially more intuitively appealing, substantially more evidence from replication of these findings evidence from replication of these findings is required. Our study, although providing is required. Our study, although providing adequate power to observe even a relatively adequate power to observe even a relatively small association between cannabis use and small association between cannabis use and COMT COMT genotype in participants with genotype in participants with schizophrenia, may not be the ideal design schizophrenia, may not be the ideal design to examine such a relationship, and other to examine such a relationship, and other longitudinal studies may be able to investilongitudinal studies may be able to investigate this with greater confidence in the gate this with greater confidence in the future. future.
In summary, we failed to find any eviIn summary, we failed to find any evidence that variation at the dence that variation at the CHRNA7 CHRNA7 or or CRN1 CRN1 locus was associated with schizolocus was associated with schizophrenia, or that the effect of variation at phrenia, or that the effect of variation at these loci was modified by use of tobacco these loci was modified by use of tobacco or cannabis respectively. Cannabis use or cannabis respectively. Cannabis use was not associated with presence of the vawas not associated with presence of the valine allele at Val line allele at Val 158 158 Met within Met within COMT COMT in in our sample, therefore our findings do not our sample, therefore our findings do not not support a previous report of a putative not support a previous report of a putative gene-environment interaction between gene-environment interaction between COMT COMT genotype and cannabis use on risk genotype and cannabis use on risk of schizophrenia. of schizophrenia.
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